Iparomlimab Biosimilar – Anti-PD1 mAb – Research Grade

Introduction:

Iparomlimab Biosimilar is an anti-PD1 monoclonal antibody (mAb) that has gained significant attention in the field of immunotherapy. This biosimilar is designed to target the programmed cell death protein 1 (PD1) receptor, which is a key regulator of the immune response. In this article, we will explore the structure, activity, and potential applications of Iparomlimab Biosimilar as a research-grade antibody.

Structure of Iparomlimab Biosimilar:

Iparomlimab Biosimilar is a recombinant humanized IgG4 monoclonal antibody that has been engineered to have a high affinity for the PD1 receptor. It is composed of two heavy chains and two light chains, each containing a variable region that specifically binds to the PD1 receptor. The antibody has a molecular weight of approximately 150 kDa and is glycosylated, meaning it contains sugar molecules that help stabilize its structure and enhance its activity.

Activity of Iparomlimab Biosimilar:

The primary function of Iparomlimab Biosimilar is to block the PD1 receptor and prevent its interaction with its ligands, PD-L1 and PD-L2. These ligands are expressed on the surface of cancer cells and other immune cells, and their binding to PD1 leads to the suppression of the immune response. By blocking this interaction, Iparomlimab Biosimilar allows the immune system to recognize and attack cancer cells, thereby enhancing the anti-tumor response. Additionally, Iparomlimab Biosimilar has been shown to promote the activation and proliferation of T-cells, which are crucial for mounting an effective immune response against cancer.

Application of Iparomlimab Biosimilar:

Iparomlimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. As a research-grade antibody, it is also widely used in laboratory studies to investigate the role of the PD1 receptor in cancer and other diseases. Furthermore, Iparomlimab Biosimilar has the potential to be used in combination with other immunotherapies, such as checkpoint inhibitors and adoptive T-cell therapy, to further enhance the anti-tumor response.

Benefits of Iparomlimab Biosimilar:

One of the main advantages of Iparomlimab Biosimilar is its high specificity for the PD1 receptor, which minimizes off-target effects and reduces the risk of adverse reactions. Moreover, as a biosimilar, it is highly similar to the reference product, making it a cost-effective alternative for researchers and clinicians. Additionally, Iparomlimab Biosimilar has a long half-life, allowing for less frequent dosing and potentially improving patient compliance.

Conclusion:

In conclusion, Iparomlimab Biosimilar is a promising anti-PD1 mAb that has the potential to revolutionize cancer treatment. Its specific targeting of the PD1 receptor and ability to enhance the immune response make it a valuable tool for both research and clinical applications. As more clinical data becomes available, Iparomlimab Biosimilar may become a key player in the field of immunotherapy, providing new hope for patients with cancer and other diseases.

ProteoGenix catalogue number PX-TA1762. For research use only.

Target: Iparomlimab Biosimilar – Anti-PD1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet